Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Christiane Segarra is active.

Publication


Featured researches published by Christiane Segarra.


Journal of Medical Virology | 1996

Comparative evaluation of three assays for the quantitation of human immunodeficiency virus type 1 RNA in plasma

Joliette Coste; Brigitte Montes; Jacques Reynes; Martine Peeters; Christiane Segarra; Jean-Pierre Vendrell; Eric Delaporte; Michel Segondy

Reverse transcriptase‐coupled polymerase chain reaction (Amplicor HIV‐1 Monitor), the branched DNA (bDNA) method (Quantiplex HIV‐1 RNA) and the nucleic acid sequence‐based assay (NASBA HIV‐1 RNA QT) were comparatively evaluated for the quantitation of human immunodeficiency virus type 1 (HIV‐1) RNA in plasma. Among 60 plasma specimens from HIV‐1 infected patients, HIV‐1 RNA was detected in 56 by Amplicor (sensitivity, 93.3%), in 41 by bDNA (sensitivity, 68.3%), and in 60 by NASBA (sensitivity, 100%). HIV‐1 RNA was not detected by any of these methods in 34/34 plasma specimens from HIV‐1‐seronegative blood donors (specificity, 100%). The HIV‐1 RNA levels as determined by the different methods were correlated significantly. The frequency of concordant results (log difference <0.50) was 80.4% between Amplicor and NASBA, 77.5% between Amplicor and bDNA, and 58.6% between bDNA and NASBA. After initiation of antiviral therapy, HIV‐1 RNA level variations observed with the three methods were similar. HIV‐1 RNA levels were inversely correlated with the CD4+ T cell counts, whereas no correlation was found with HIV‐1 p24‐antigen levels. When the methods were evaluated for reproducibility, coefficients of variation ranged from 11% to 40% for Amplicor, from 6% to 35% for bDNA, and from 13% to 62% for NASBA. Quantitation of HIV‐1 RNA in culture supernatants from HIV‐1 subtype A to H strains showed that bDNA can be used to quantitate RNA from all HIV‐1 subtypes, whereas Amplicor failed to detect RNA from subtype A strains and NASBA subtype G strains.


Science Translational Medicine | 2016

Detection of prions in the plasma of presymptomatic and symptomatic patients with variant Creutzfeldt-Jakob disease

Daisy Bougard; Jean-Philippe Brandel; Maxime Bélondrade; Vincent Béringue; Christiane Segarra; Hervé Fleury; Jean-Louis Laplanche; Charly Mayran; Simon Nicot; Alison Green; Arlette Welaratne; David Narbey; Chantal Fournier-Wirth; Richard Knight; Robert G. Will; Pierre Tiberghien; Stéphane Haïk; Joliette Coste

A sensitive blood diagnostic assay can identify patients with variant Creutzfeldt-Jakob disease before symptoms appear and during the clinical phase. A new blood test for prion diseases Variant Creutzfeldt-Jakob disease (vCJD) is a human prion disease that can be transmitted from person to person through medical procedures. The development of a diagnostic blood test is an urgent priority. Bougard et al. describe a sensitive and specific blood test based on a prion capture step and an amplification method. This test for vCJD was very accurate and worked not only for blood samples from patients suffering from vCJD but also for samples taken from two individuals 1.3 and 2.6 years before they developed clinical symptoms. This blood test has important implications for transfusion medicine and public health. Variant Creutzfeldt-Jakob disease (vCJD) is a human prion disease resulting from the consumption of meat products contaminated by the agent causing bovine spongiform encephalopathy. Evidence supporting the presence of a population of silent carriers that can potentially transmit the disease through blood transfusion is increasing. The development of a blood-screening assay for both symptomatic vCJD patients and asymptomatic carriers is urgently required. We show that a diagnostic assay combining plasminogen-bead capture and protein misfolding cyclic amplification (PMCA) technologies consistently detected minute amounts of abnormal prion protein from French and British vCJD cases in the required femtomolar range. This assay allowed the blinded identification of 18 patients with clinical vCJD among 256 plasma samples from the two most affected countries, with 100% sensitivity [95% confidence interval (CI), 81.5 to 100%], 99.2% analytical specificity (95% CI, 95.9 to 100%), and 100% diagnostic specificity (95% CI, 96.5 to 100%). This assay also allowed the detection of silent carriage of prions 1.3 and 2.6 years before the clinical onset in two blood donors who later developed vCJD. These data provide a key step toward the validation of this PMCA technology as a blood-based diagnostic test for vCJD and support its potential for detecting presymptomatic patients, a prerequisite for limiting the risk of vCJD transmission through blood transfusion.


PLOS ONE | 2013

Plasminogen-Based Capture Combined with Amplification Technology for the Detection of PrPTSE in the Pre-Clinical Phase of Infection

Christiane Segarra; Daisy Bougard; Mohammed Moudjou; Hubert Laude; Vincent Béringue; Joliette Coste

Background Variant Creutzfeldt-Jakob disease (vCJD) is a neurodegenerative infectious disorder, characterized by a prominent accumulation of pathological isoforms of the prion protein (PrPTSE) in the brain and lymphoid tissues. Since the publication in the United Kingdom of four apparent vCJD cases following transfusion of red blood cells and one apparent case following treatment with factor VIII, the presence of vCJD infectivity in the blood seems highly probable. For effective blood testing of vCJD individuals in the preclinical or clinical phase of infection, it is considered necessary that assays detect PrPTSE concentrations in the femtomolar range. Methodology/Principal Findings We have developed a three-step assay that firstly captures PrPTSE from infected blood using a plasminogen-coated magnetic-nanobead method prior to its serial amplification via protein misfolding cyclic amplification (PMCA) and specific PrPTSE detection by western blot. We achieved a PrPTSE capture yield of 95% from scrapie-infected material. We demonstrated the possibility of detecting PrPTSE in white blood cells, in buffy coat and in plasma isolated from the blood of scrapie-infected sheep collected at the pre-clinical stage of the disease. The test also allowed the detection of PrPTSE in human plasma spiked with a 10−8 dilution of vCJD-infected brain homogenate corresponding to the level of sensitivity (femtogram) required for the detection of the PrPTSE in asymptomatic carriers. The 100% specificity of the test was revealed using a blinded panel comprising 96 human plasma samples. Conclusion/Significance We have developed a sensitive and specific amplification assay allowing the detection of PrPTSE in the plasma and buffy coat fractions of blood collected at the pre-clinical phase of the disease. This assay represents a good candidate as a confirmatory assay for the presence of PrPTSE in blood of patients displaying positivity in large scale screening tests.


International Journal of Nanomedicine | 2015

Magnetic microparticle-based multimer detection system for the detection of prion oligomers in sheep.

Kuntaek Lim; Su Yeon Kim; Byoung-sub Lee; Christiane Segarra; Sungmin Kang; Young-Ran Ju; Mary Jo Schmerr; Joliette Coste; SangYun Kim; Takashi Yokoyama; Seong Soo A. An

Transmissible spongiform encephalopathies (TSEs) are zoonotic fatal neurodegenerative diseases in animals and humans. TSEs are commonly known as bovine spongiform encephalopathy in cattle, scrapie in sheep and goats, chronic wasting disease in cervids, and Creutzfeldt–Jakob disease in humans. The putative transmissible agents are infectious prion proteins (PrPSc), which are formed by the conversion of the normal prion protein on the glycoprotein cell surface in the presence of other PrPSc. Reports of the transmission of TSEs through blood raised considerable concern about the safety of blood and blood products. To address this issue, many laboratories attempted to develop a sensitive and accurate blood diagnostic test to detect PrPSc. Previously, we reported that, compared to normal controls, the multimer detection system (MDS) was more efficient in detecting PrPSc in infected hamster brain homogenate, mouse plasma spiked with purified PrPSc from scrapie mouse brain, and scrapie-infected hamster plasmas. MDS differentiates prion multimers from the cellular monomer through the multimeric expression of epitopes on prion multimers, in contrast to the monomeric form. In this study, MDS detected PrPSc in plasma samples from scrapie-infected sheep expressing clinical symptoms, demonstrating 100% sensitivity and specificity in these samples. Plasma samples from asymptomatic lambs at the preclinical stage (8-month-old naturally infected offspring of scrapie-infected parents expressing a highly susceptible genotype) tested positive with 50% sensitivity and 100% specificity. In the first of two coded analyses using clinical scrapie-infected sheep and normal healthy samples, MDS successfully identified all but one of the clinical samples with 92% sensitivity and 100% specificity. Similar results were obtained in the second coded analysis using preclinical samples. MDS again successfully identified all but one of the samples with 87% sensitivity and 100% specificity. The false-negative sample was subjected to a protease pretreatment. In conclusion, MDS could accurately detect scrapie in plasma samples at both preclinical and clinical stages. From these studies, we conclude that MDS could be a promising tool for the early diagnosis of TSEs from blood samples.


PLOS ONE | 2009

Prion Protein Expression and Processing in Human Mononuclear Cells: The Impact of the Codon 129 Prion Gene Polymorphism

Christiane Segarra; Sylvain Lehmann; Joliette Coste

Background So far, all clinical cases of new variant Creutzfeldt-Jakob disease (vCJD), thought to result from the Bovine Spongiform Encephalopathy (BSE) prion agent, have shown Methionine–Methionine (M/M) homozygosity at the M129V polymorphism of the PRNP gene. Although established, this relationship is still not understood. In both vCJD and experimental BSE models prion agents do reach the bloodstream, raising concerns regarding disease transmission through blood transfusion. Methodology/Principal Findings We investigated the impact of the M129V polymorphism on the expression and processing of the prion protein in human peripheral blood mononuclear cells (PBMCs) from three blood donor populations with Methionine-Methionine (M/M), Valine-Valine (V/V) and M/V genotypes. Using real-time PCR, ELISA and immunoblot assays we were unable to find differences in prion protein expression and processing relating to the M129V polymorphism. Conclusions/Significance These results suggest that in PBMCs, the M129V PrP polymorphism has no significant impact on PrP expression, processing and the apparent glycoform distribution. Prion propagation should be investigated further in other cell types or tissues.


Arthritis & Rheumatism | 1996

SICCA syndrome associated with hepatitis C virus infection

Christian Jorgensen; Marie-Christine Legouffe; P Perney; Joliette Coste; Barbara Tissot; Christiane Segarra; Bologna C; Laurent Bourrat; Bernard Combe; F. Blanc; Sany J


Journal of Acquired Immune Deficiency Syndromes | 1997

Effect of HIV-1 genetic diversity on HIV-1 RNA quantification in plasma: comparative evaluation of three commercial assays.

Joliette Coste; Brigitte Montes; J. Reynes; Martine Peeters; Christiane Segarra; Eric Delaporte; Michel Segondy


Journal of Immunological Methods | 2004

Use of serial analysis of gene expression (SAGE) technology reveals new granulocytic markers

Gérald Bertrand; Joliette Coste; Christiane Segarra; Jean-François Schved; Thérèse Commes; Jacques Marti


Archive | 2012

Nanobeads covered with plasminogen as a direct support for cyclic amplification of the prion protein PrPSC

Christiane Segarra; Joliette Coste Van Der Luur; Daisy Bougard


Archive | 2012

Nanobilles recouvertes de plasminogène comme support direct d'amplification cyclique de la protéine prion PrPsc

Christiane Segarra; Van Der Luur Joliette Coste; Daisy Bougard

Collaboration


Dive into the Christiane Segarra's collaboration.

Top Co-Authors

Avatar

Joliette Coste

University of Montpellier

View shared research outputs
Top Co-Authors

Avatar

Daisy Bougard

University of Montpellier

View shared research outputs
Top Co-Authors

Avatar

Michel Segondy

University of Montpellier

View shared research outputs
Top Co-Authors

Avatar

Vincent Béringue

Institut national de la recherche agronomique

View shared research outputs
Top Co-Authors

Avatar

Eric Delaporte

Institut de recherche pour le développement

View shared research outputs
Top Co-Authors

Avatar

Martine Peeters

Institut de recherche pour le développement

View shared research outputs
Top Co-Authors

Avatar

Bernard Combe

University of Montpellier

View shared research outputs
Top Co-Authors

Avatar

Bologna C

University of Montpellier

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Charly Mayran

University of Montpellier

View shared research outputs
Researchain Logo
Decentralizing Knowledge